Abstract 2323
Background
It is well documented that survival of CRC is dependent on early diagnosis. In England, the Department of Health’s cancer policy states that patients with symptoms of suspected cancer must be seen and assessed by the specialist team within 2 weeks of a referral by their General Practitioner (GP). The traditional 2 week wait (2ww) referral route involves these patients being seen in clinic within 2 weeks, where they are assessed and an investigation is booked, taking up to 4 weeks for first investigation and diagnosis. We have introduced a novel Straight to Test / CTAP for these patients, which rationalises the patient journey, ensuring that the patient has the right test first time, without delay.
Methods
Our service is a Consultant Nurse led Straight to Test / CTAP. All 2ww patients referred by the GP with suspected CRC are assessed via the CTAP. Upon receipt of the electronic referral from their GP, a colorectal assessment is carried out via telephone within 48 hours of referral by the Consultant nurse or a member or her specialist nursing team. The patient is then triaged for the most appropriate investigation, according to a protocol, which is then booked within 2 weeks of the GPs referral.
Results
The CTAP has been running now for 5 years with over 4000 patients being assessed via this route. In 2017 & 2018 the cancer yield from our service was 4% which matches that of traditional out-patient assessments routes. However we were able to reduce the patient pathway by 10 days by the introduction of the CTAP. 70% of patients had an endoscopy procedure as their first investigation and 28% had a radiological investigation (usually CT Colonography). 90% of patients had their diagnosis or given the all clear by day 14.
Conclusions
This pathway has significantly shortened the patient’s pathway and time diagnosis for our patients, meaning that those patients with CRC are diagnosed by day 14. Patients with other pathologies are also diagnosed quicker and those patients with no serious pathology are reassured and discharged back to their GP We have managed to reduce waiting times from referral to diagnosis and to ensure all patients on the 2ww pathway have a more streamline patient focused experience, avoiding unnecessary hospital visits.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
4506 - Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity
Presenter: Adel Samson
Session: Poster Display session 3
Resources:
Abstract
1631 - Randomized phase 2 clinical trial of NY-ESO-1 protein vaccine combined with cholesteryl pullulan (CHP-NY-ESO-1) in resected esophageal cancer patients
Presenter: Shinichi Kageyama
Session: Poster Display session 3
Resources:
Abstract
4244 - T cell repertoire sequencing reveals dynamics of response to dendritic cell vaccine plus dasatinib for checkpoint blockade resistant metastatic melanoma
Presenter: Luca Quagliata
Session: Poster Display session 3
Resources:
Abstract
5791 - Ixovex, a novel oncolytic E1B-mutated adenovirus
Presenter: Mohiemen Anwar
Session: Poster Display session 3
Resources:
Abstract
4170 - Anti-CSPG4 DNA vaccination as a promising strategy for the treatment of CSPG4+ tumors: a comparative oncology trial
Presenter: Federica Riccardo
Session: Poster Display session 3
Resources:
Abstract
5780 - Antitumor activity, immunogenicity and safety of a novel PD-1 vaccine in combination with two chimeric HER-2 peptide vaccine in syngeneic Balb/c, C57Bl/6 models and in beagle dogs
Presenter: Pravin Kaumaya
Session: Poster Display session 3
Resources:
Abstract
5860 - Maternal immunization against ALK as a weapon to fight neuroblastoma
Presenter: Giuseppina Barutello
Session: Poster Display session 3
Resources:
Abstract
4720 - Phase 1 study evaluating safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-428, first-in-class mesothelin (MSLN)-CD40 bispecific, in patients (pts) with advanced solid tumors
Presenter: Jason Luke
Session: Poster Display session 3
Resources:
Abstract
5717 - Anti-PD-L1/IL-15 fusion protein generates robust adaptive immune gene signatures in tumors leading to tumor inhibition and memory responses
Presenter: Stella Martomo
Session: Poster Display session 3
Resources:
Abstract
1802 - Evaluation of the anti-tumor efficacy and immune effects of N-809, a novel IL-15 superagonist/anti-PD-L1 bispecific agent
Presenter: Kristin Hicks
Session: Poster Display session 3
Resources:
Abstract